The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

被引：0
|
作者：
Ashok Jha
Alex Upton
William C. N. Dunlop
Ron Akehurst
机构：
[1] Mundipharma International Ltd.,School of Health and Related Research (ScHARR)
[2] Abacus International,undefined
[3] University of Sheffield,undefined
[4] BresMed Health Solutions Limited,undefined
[5] Northchurch Business Centre,undefined
来源：
Advances in Therapy | 2015年 / 32卷
关键词：
Ankylosing spondylitis; Biosimilar; Crohn’s disease; Infliximab; Psoriasis; Psoriatic arthritis; Remicade; Remsima; Rheumatoid arthritis; Ulcerative colitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：742 / 756
页数：14
相关论文
共 50 条
  • [1] The Budget Impact of Biosimilar Infliximab (RemsimaA®) for the Treatment of Autoimmune Diseases in Five European Countries
    Jha, Ashok
    Upton, Alex
    Dunlop, William C. N.
    Akehurst, Ron
    ADVANCES IN THERAPY, 2015, 32 (08) : 742 - 756
  • [2] BUDGET IMPACT ANALYSIS OF INTRODUCING BIOSIMILAR INFLIXIMAB FOR THE TREATMENT OF AUTO IMMUNE DISORDERS IN FIVE EUROPEAN COUNTRIES
    Jha, A.
    Upton, A.
    Dunlop, W.
    VALUE IN HEALTH, 2014, 17 (07) : A525 - A525
  • [3] Budget impact analysis of introducing biosimilar infliximab for the treatment of gastro intestinal disorders in five European countries
    Jha, A.
    Dunlop, W.
    Upton, A.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S427 - S427
  • [4] BUDGET IMPACT ANALYSIS OF BIOSIMILAR INFLIXIMAB TREATMENT FOR RHEUMATOID ARTHRITIS IN SIX CENTRAL EUROPEAN COUNTRIES
    Brodszky, V
    Pentek, M.
    Baji, P.
    Balogh, O.
    Hever N, V.
    Gulacsi, L.
    VALUE IN HEALTH, 2013, 16 (07) : A558 - A558
  • [5] BUDGET IMPACT ANALYSIS OF BIOSIMILAR INFLIXIMAB FOR THE TREATMENT OF CROHN'S DISEASE IN SIX CENTRAL EASTERN EUROPEAN COUNTRIES
    Brodszky, V
    Gulacsi, L.
    Balogh, O.
    Baji, P.
    Rencz, F.
    Pentek, M.
    VALUE IN HEALTH, 2014, 17 (07) : A364 - A364
  • [6] Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
    Brodszky, Valentin
    Baji, Petra
    Balogh, Orsolya
    Pentek, Marta
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 : S65 - S71
  • [7] BUDGET IMPACT OF SUBCUTANEOUS INFLIXIMAB IN COMPARISON TO INTRAVENOUS INFLIXIMAB IN THE MANAGEMENT OF AUTOIMMUNE DISEASES IN GREECE
    Mortaki, K.
    Rigopoulos, P.
    Stratopoulos, A.
    Avgerinou, M.
    Kougioumtzoglou, I
    VALUE IN HEALTH, 2022, 25 (12) : S68 - S68
  • [8] Budget impact analysis of infliximab biosimilar: the Italian scenery
    Lucioni, Carlo
    Mazzi, Silvio
    Caporali, Roberto
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2015, 2 (02) : 78 - 88
  • [9] UPTAKE OF BIOSIMILAR INFLIXIMAB: BUDGET SAVINGS OR MARKET EXPANSION ACROSS COUNTRIES?
    Kim, Y.
    Kwon, H. Y.
    Godman, B.
    Moorkens, E.
    Simoens, S.
    Bae, S.
    VALUE IN HEALTH, 2019, 22 : S425 - S425
  • [10] Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre
    Kolar, M.
    Duricova, D.
    Bortlik, M.
    Hruba, V.
    Machkova, N.
    Mitrova, K.
    Malickova, K.
    Lukas, M., Jr.
    Lukas, Milan
    DIGESTIVE DISEASES, 2017, 35 (1-2) : 91 - 100
12345